EpiSwitch COVID Severity Test (CST) is an advanced blood test that will
help your patients understand their risk of a severe immune response to COVID-19.
Watch video to learn moreCOVID-19 poses to an individual.
EpiSwitch CST is the first and only commercially-available blood test for the prediction of COVID-19 severity in ANY adult, independent of COVID-19 status. The test can help patients understand - and cope - with their individual level of risk.
EpiSwitch CST is designed to provide healthcare professionals (HCPs) and their adult patients with actionable, decision-making information regarding infection mitigation during the COVID-19 pandemic based on the unique 3D genetic immune profile of each individual.
The test is variant-agnostic so it identifies risk due to regular SARS-CoV-2, as well as delta, omicron, and other strains.

How EpiSwitch CST can help

ENHANCED, PERSONALIZED GUIDANCE

PREDICT RESPONSE TO INFECTION IN ANY ADULT

HIGH CONFIDENCE FOR HCPs
EpiSwitch CST provides HCPs with an
easy-to-understand molecular assessment of risk for a severe immune response to COVID-19.
Interpreting the EpiSwitch CST report
The EpiSwitch CST report includes clear guidance for HCPs to interpret an adult patient’s risk score and formulate an effective management plan.
Individuals with a high-risk EpiSwitch CST score are at increased probability of experiencing a severe immune response to COVID-19. Such individuals should be counseled on their risk level and may benefit from a mitigation-strategy review to avoid infection. In the event of infection, early use of medications or other interventions are recommended.
Those at average risk should not be construed as having no risk; complications that do not require critical care are possible.
Risk results do not provide information about an individual’s risk of becoming infected. Regardless of risk results, government and local health-department guidelines must be followed to avoid transmitting the virus.
Features of EpiSwitch CST
COVID-19.
EpiSwitch CST measures six genetic markers to determine risk category. EpiSwitch CST was developed using epigenetic data obtained from COVID-19 patients in North America, South America, and Europe.
EpiSwitch CST Provider Guide

Become an EpiSwitch CST testing center or a registered EpiSwitch CST healthcare provider
Order EpiSwitch CST

Provider FAQ


Existing COVID-19 tests fall into two general categories. The first category detects the presence of the SARS-CoV-2 virus and diagnoses an active coronavirus infection. The second category detects antibodies generated by the immune system in response to - and provide an indication - of past coronavirus infection.
EpiSwitch CST gives your healthcare provider (HCP) forward-looking information about your risk of developing a severe immune reaction that may require hospitalization if you become infected with the SARS-CoV-2 virus.

CLIA, Clinical Laboratory Improvement Amendments




